[{"orgOrder":0,"company":"Omniose","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omniose \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Omniose \/ AstraZeneca"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"3","companyTruncated":"Locus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"Eclipse Bioinnovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Eclipse Bioinnovations","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Bioinnovations \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Eclipse Bioinnovations \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ Merck & Co"},{"orgOrder":0,"company":"PostEra","sponsor":"Breyer Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PostEra \/ Breyer Capital","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ Breyer Capital"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Poseida Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Poseida Therapeutics, Inc"},{"orgOrder":0,"company":"PostEra","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"PostEra \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ National Institutes of Health"},{"orgOrder":0,"company":"Ardigen","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ardigen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardigen \/ CVC Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Ardigen \/ CVC Capital Partners"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Metaba","highestDevelopmentStatusID":"3","companyTruncated":"MAX BioPharma \/ Metaba"},{"orgOrder":0,"company":"Phare Bio","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Phare Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phare Bio \/ ARPA-H","highestDevelopmentStatusID":"3","companyTruncated":"Phare Bio \/ ARPA-H"},{"orgOrder":0,"company":"ArrePath","sponsor":"Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"ArrePath","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArrePath \/ Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"ArrePath \/ Venture Fund"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GreenLight Biosciences \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"GreenLight Biosciences \/ Serum Institute of India"},{"orgOrder":0,"company":"Primrose Bio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Primrose Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primrose Bio \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"Primrose Bio \/ Serum Institute of India"},{"orgOrder":0,"company":"Tiba Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Tiba Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiba Biotech \/ BARDA","highestDevelopmentStatusID":"3","companyTruncated":"Tiba Biotech \/ BARDA"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Vaccine and Immunotherapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Prophylactic Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Vaccine and Immunotherapy Center","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Vaccine and Immunotherapy Center"},{"orgOrder":0,"company":"MalarVx","sponsor":"HDT Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MalarVx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MalarVx \/ HDT Biotech","highestDevelopmentStatusID":"3","companyTruncated":"MalarVx \/ HDT Biotech"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"VitriVax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Hexavalent Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"VitriVax","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VitriVax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"VitriVax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"Toll-like-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"Moderna Therapeutics \/ CEPI"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":"3","companyTruncated":"Ancilia Bioscience \/ Safar Partners"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target